AJAna Janic

Ana Janic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Janic has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nuclear adenosine metabolism defines a metabolic vulnerability unmasked by TP53 loss

    by Julia Urgel-Solas, Anna Benito-Ferrer, Laura Ortet, Savvas Kourtis, Etna Abad, Albert Coll Manzano, Anna Shevzov-Zebrun, Camilla Reiter Elbæk, Carlos M. Martínez, Matthew G Vander Heiden, et al.

    Metabolic adaptation is essential for cells experiencing chronic genomic stress, yet how such adaptations are organized at the nuclear level remains poorly understood. Loss of TP53 is associated with elevated genomic instability, DNA damage and altered metabolic requirements, creating context specific dependencies. Here, we identify a requirement for de novo purine biosynthesis in TP53-deficient cells, with a pronounced dependence on adenosine related metabolism. Perturbation of purine synthesis increases DNA damage and reduces nuclear ATP availability, particularly in TP53-deficient cells, and is accompanied by a rapid increase in histone methylation. This chromatin response is also induced by acute DNA damage and occurs with fast kinetics, indicating that histone methylation is an early, intrinsic feature of the nuclear stress response rather than a secondary epigenetic remodeling. Interfering with histone methylation is associated with reduced nuclear ATP levels and impaired DNA damage resolution, linking chromatin state to nuclear energy homeostasis. Genetic disruption of the purine biosynthesis enzyme PFAS selectively impairs the growth of TP53-deficient tumours in vivo , establishing the physiological relevance of this metabolic dependency. Together, these findings reveal nuclear adenosine metabolism as a compartmentalised adaptive response to genotoxic stress and highlight chromatin associated methylation as a key feature of nuclear metabolic regulation unmasked by TP53 loss.

  • Open Access

    PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity

    by Neus Martínez-Bosch, Noemí Manero-Rupérez, Núria Vázquez-Bellón, Bennett Nickell-Hernández, Cristina Ventura-Blanch, Nura Lutfi, Carmen G. Lechuga, Carlos Martínez, Mireia Moreno, Coral Ampurdanés, et al.

    Pancreatic cancer represents one of the most lethal tumors, characterized by an immunosuppressive microenvironment and a lack of cytotoxic immune cell infiltrates, which confer resistance to immunotherapy. Here, we demonstrate that deletion of poly(ADP-ribose) polymerase 2 (PARP2) in a Myc -driven mouse model of pancreatic cancer delays tumor progression and increases survival. Mechanistically, PARP2 loss induces enrichment of pathways associated with genomic instability and replicative stress, leading to increased γH2AX, chromosomal instability, and micronuclei accumulation. In addition to these tumor-intrinsic effects, PARP2 deletion reshapes the tumor microenvironment, promoting infiltration of cytotoxic T and natural killer cells while reducing immunosuppressive cell populations, enhancing antitumor cytotoxicity. These findings are recapitulated in a Kras G12D -driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease.


  • Open Access

    Dual inhibition of the nonsense mediated mRNA decay enhances tumour immunogenicity, drives immunoediting, and potentiates checkpoint blockade

    by Ivan Zadra, Davor Orsolic, Dimitri Kounis, Mario Acera, Guillermo Palou Márquez, Etna Abad, Laura Ortet, Anna Benito, Yacine Kharraz, Carlos M. Martínez, et al.

    Immune checkpoint blockade has transformed cancer therapy, but current biomarkers such as tumour mutation burden often fail to reliably predict clinical benefit. One proposed reason for this discrepancy is the activity of nonsense-mediated mRNA decay (NMD), a cellular quality-control pathway that degrades mutant transcripts, potentially reducing the presentation of neoantigens that would otherwise stimulate anti-tumour immunity. To address this, we identified publicly available small-molecule inhibitors targeting the NMD factors SMG5 and SMG7 (NMDi), which we have prioritise as the NMD components most strongly associated with NMD efficiency across TCGA tumours, and evaluated their therapeutic potential in vivo . In a syngeneic, DNA repair deficient mouse model of lung adenocarcinoma, NMDi treatment alone substantially reduced tumour burden, and its combination with anti–PD-1 therapy led to additive benefit either treatment alone. These effects were immune-dependent and specifically required CD8□ T cells. Transcriptomic and single-cell analyses revealed that NMDi reprograms the tumour immune microenvironment, enriching for clonally expanded, cytotoxic CD8□ T cells and altering macrophage states toward those associated with tumour regression. Whole-genome sequencing of tumours revealed that NMDi also promotes immunoediting, leading to negative selection against immunogenic mutations and coding indels, with selective pressure comparable to or greater than that induced by anti–PD-1 treatment. Guided by these results, we generated a new protein language model trained on tumour mutations that can identify neopeptides with immunogenic properties, revealing that the NMDi tumour landscape provides a rich genomic and immunopeptidomic setting for exposing neoantigens that evade immunoediting. Together, these pre-clinical and integrative genomic-transcriptomic insights position NMD inhibition as a promising immunostimulatory strategy that can potentiate immune checkpoint blockade efficacy in tumours.


  • Open Access

    A novel mismatch repair deficient lung adenocarcinoma model for immunotherapy research

    by Ivan Zadra, Etna Abad, Anastasia Krasko, Víctor Cerdán Porqueras, Marc Subirana-Granés, Diana Reyes, Pablo Borredat, Lorenzo Pasquali, Jose Aramburu, Cristina López-Rodríguez, et al.


  • Open Access

    Site-specific immunogenicity and anti-PD1 response in mismatch repair deficient lung adenocarcinoma models

    by Etna Abad, Ivan Zadra, Anastasia Krasko, Marc Subirana-Granés, Diana Reyes, Pablo Borredat, Lorenzo Pasquali, Jose Aramburu, Cristina López-Rodríguez, Ana Janic

    Immunotherapy has revolutionized cancer treatment, yet responses vary significantly based on tumour characteristics and microenvironment. Here, we developed and analysed subcutaneous and orthotopic immunocompetent mice models of mismatch repair-deficient (dMMR) lung adenocarcinoma (LUAD) by selectively ablating Mlh1. Subcutaneous tumours demonstrated partial sensitivity to anti-PD1 therapy, characterized by tumour volume reduction without significant changes in immune infiltration. In contrast, orthotopic tumours exhibited robust responses, with substantial reductions in tumour burden, enhanced immune infiltration, and increased CD4+memory T cells, highlighting the critical role of anatomical site and tumour microenvironment in shaping immunotherapy outcomes. Our findings emphasise the relevance of orthotopic models for preclinical evaluation and suggest that they more accurately reflect clinical responses to immune checkpoint blockade in dMMR LUAD.

  • Open Access

    The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability

    by Etna Abad, Jérémy Sandoz, Gerard Romero, Ivan Zadra, Julia Urgel-Solas, Pablo Borredat, Savvas Kourtis, Laura Ortet, Carlos M. Martínez, Donate Weghorn, et al.

    Background: TP53, the most frequently mutated gene in human cancers, orchestrates a complex transcriptional program crucial for cancer prevention. While certain TP53-dependent genes have been extensively studied, others, like the recently identified RNF144B, remained poorly understood. This E3 ubiquitin ligase has shown potent tumor suppressor activity in murine Eμ Myc-driven lymphoma, emphasizing its significance in the TP53 network. However, little is known about its targets and its role in cancer development, requiring further exploration. In this work, we investigate RNF144B's impact on tumor suppression beyond the hematopoietic compartment in human cancers. Methods: Employing TP53 wild-type cells, we generated models lacking RNF144B in both non-transformed and cancerous cells of human and mouse origin. By using proteomics, transcriptomics, and functional analysis, we assessed RNF144B's impact in cellular proliferation and transformation. Through in vitro and in vivo experiments, we explored proliferation, DNA repair, cell cycle control, mitotic progression, and treatment resistance. Findings were contrasted with clinical datasets and bioinformatics analysis. Results: Our research underscores RNF144B's pivotal role as a tumor suppressor, particularly in lung adenocarcinoma. In both human and mouse oncogene-expressing cells, RNF144B deficiency heightened cellular proliferation and transformation. Proteomic and transcriptomic analysis revealed RNF144B's novel function in mediating protein degradation associated with cell cycle progression, DNA damage response and genomic stability. RNF144B deficiency induced chromosomal instability, mitotic defects, and correlated with elevated aneuploidy and worse prognosis in human tumors. Furthermore, RNF144B-deficient lung adenocarcinoma cells exhibited resistance to cell cycle inhibitors that induce chromosomal instability. Conclusions: Supported by clinical data, our study suggests that RNF144B plays a pivotal role in maintaining genomic stability during tumor suppression. Graphical


  • Open Access

    Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control?

    by Ana Janic, Etna Abad, Ivano Amelio

    Genomic instability, a hallmark of cancer, is a direct consequence of the inactivation of the tumor suppressor protein p53. Genetically modified mouse models and human tumor samples have revealed that p53 loss results in extensive chromosomal abnormalities, from copy number alterations to structural rearrangements. In this perspective article we explore the multifaceted relationship between p53, genomic stability, and epigenetic control, highlighting its significance in cancer biology. p53 emerges as a critical regulator of DNA repair mechanisms, influencing key components of repair pathways and directly participating in DNA repair processes. p53 role in genomic integrity however extends beyond its canonical functions. p53 influences also epigenetic landscape, where it modulates DNA methylation and histone modifications. This epigenetic control impacts the expression of genes involved in tumor suppression and oncogenesis. Notably, p53 ability to ensure cellular response to DNA demethylation contributes to the maintenance of genomic stability by preventing unscheduled transcription of repetitive non-coding genomic regions. This latter indicates a causative relationship between the control of epigenetic stability and the maintenance of genomic integrity in p53-mediated tumor suppression. Understanding these mechanisms offers promising avenues for innovative therapeutic strategies targeting epigenetic dysregulation in cancer and emphasizes the need for further research to unravel the complexities of this relationship. Ultimately, these insights hold the potential to transform cancer treatment and prevention strategies.


  • Open Access

    Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice

    by Margs S. Brennan, Kerstin Brinkmann, Gerard Romero Sola, Geraldine Healey, Leonie Gibson, Lahiru Gangoda, Margaret A. Potts, Elizabeth Lieschke, Stephen Wilcox, Andreas Strasser, et al.

    Transcriptional activation of target genes is essential for TP53-mediated tumour suppression, though the roles of the diverse TP53-activated target genes in tumour suppression remains poorly understood. Knockdown of ZMAT3, an RNA-binding zinc-finger protein involved in regulating alternative splicing, in haematopoietic cells by shRNA caused leukaemia only with the concomitant absence of the PUMA and p21, the critical effectors of TRP53-mediated apoptosis and cell cycle arrest respectively. We were interested to further investigate the role of ZMAT3 in tumour suppression beyond the haematopoietic system. Therefore, we generated Zmat3 knockout and compound gene knockout mice, lacking Zmat3 and p21, Zmat3 and Puma or all three genes. Puma−/−p21−/−Zmat3−/− triple knockout mice developed tumours at a significantly higher frequency compared to wild-type, Puma−/−Zmat3−/− or p21−/−Zmat3−/−deficient mice. Interestingly, we observed that the triple knockout and Puma−/−Zmat3−/− double deficient animals succumbed to lymphoma, while p21−/−Zmat3−/− animals developed mainly solid cancers. This analysis suggests that in addition to ZMAT3 loss, additional TRP53-regulated processes must be disabled simultaneously for TRP53-mediated tumour suppression to fail. Our findings reveal that the absence of different TRP53 regulated tumour suppressive processes changes the tumour spectrum, indicating that different TRP53 tumour suppressive pathways are more critical in different tissues.


  • Open Access

    Adaptation to ARF6-depletion in KRAS-driven PDAC is abolished by targeting TLR2

    by Ritobrata Ghose, Shubhamay Das, Julia Urgel-Solas, Fabio Pezzano, Debayan Datta, Upamanyu Ghose, Antoni Ganez Zapater, Natalia Pardo Lorente, Lorena Espinar Calvo, Laura Garcia, et al.

    SUMMARY: Metastasis is responsible for nearly 90% of all cancer-related deaths. Despite global efforts to prevent aggressive tumours, cancers such as pancreatic ductal adenocarcinoma (PDAC) are poorly diagnosed in the primary stage, resulting in lethal metastatic disease. RAS mutations are known to promote tumour spread, with mutant KRAS present in up to 90% of cases. Until recently, mutant KRAS remained untargeted and, despite the recent development of inhibitors, results show that tumour cells develop resistance. Another strategy for targeting mutant KRAS-dependent PDAC proliferation and metastasis may come from targeting the downstream effectors of KRAS. One such axis, which controls tumour proliferation, invasiveness and immune evasion, is represented by ARF6-ASAP1. Here we show that targeting ARF6 results in adaptive rewiring that can restore proliferation and invasion potential over time. Using time-series RNA and ATAC sequencing approaches, we identified TLR-dependent NFκB, TNFα and hypoxia signalling as key drivers of adaptation in ARF6-depleted KRAS-dependent PDAC. Using in vitro and in vivo assays, we show that knocking down TLR2 with ARF6 significantly reduces proliferation, migration and invasion. Taken together, our data shed light on a novel co-targeting strategy with the therapeutic potential to counteract PDAC proliferation and metastasis. GRAPHICAL SUMMARY:

  • Open Access

    The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability

    by Etna Abad, Jeremy Sandoz, Gerard Romero, Julia Urgel-Solas, Pablo Borredat, Savvas Kourtis, Laura Ortet, Carlos Martínez, Donate Weghorn, Sara Sdelci, et al.

    The tumor suppressor protein TP53 regulates a vast transcriptional program that serves protective mechanisms against cancer development. However, the complexity of this program makes it difficult to unravel the role of each of its targets in TP53-mediated tumour suppression. ​​Knockdown of RNF144B, a E3-ubiquitin ligase transcriptionally regulated by TP53, enhanced the rate of tumour development and severity of malignant disease in the context of murine c-MYC-driven lymphomagenesis. Here we asked whether RNF144B has an impact on tumor suppression beyond the hematopoietic compartment. Integrative transcriptomics, proteomics, genomics and functional analysis of human and mouse oncogene-expressing cells with TP53 wild-type revealed a role for RNF144B in coordinating cellular proliferation and transformation, DNA repair and genome stability. Moreover, we show that in the context of lung adenocarcinomas, RNF144B deficiency leads to resistance to cytotoxic drugs that induce DNA damage and chromosomal instability, and that patients have a worse disease-survival overall. Supported by clinical data, our study suggests that RNF144B governs genomic stability during transformation suppression, which could explain its inactivation in human cancers.